Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.4
4.8
Journals
Biomolecules
Special Issues
Stem Cells in Musculoskeletal Tissue Engineering
share announcement

Stem Cells in Musculoskeletal Tissue Engineering

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Bio-Engineered Materials".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 796

Special Issue Editors

Dr. Chenshuang Li

E-Mail Website
Guest Editor
Department of Orthodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Interests: craniofacial; tissue regeneration; arthritis; orthodontics
Special Issues, Collections and Topics in MDPI journals
Dr. Zhong Zheng

E-Mail Website
Guest Editor
Department of Periodontics, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Interests: wound healing; tissue regeneration; cartilage; tendon; stem cell; cell reprogramming
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

A wide range of acute and chronic conditions, including traumatic, degenerative, malignant, and congenital disorders, commonly induce musculoskeletal deficiency, significantly challenging patients’ daily lives due to substantial tissue deficiency. Unfortunately, the innate self-healing capacity of musculoskeletal tissue is often inadequate for larger defects over a critical size. In response, pluripotent or multipotent cell-based therapeutics are being broadly investigated. In this special issue, we aim to provide the latest updates in this area, with specific focuses on:

  1. Safety: In addition to embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), whose applications are hindered by their inherent tumorigenic nature, mesenchymal stromal cells (MSCs) have been found to acquire chromosomal aberrations, undergo spontaneous tumorigenic transformation, participate ad promote tumor development. Therefore, the safety concerns for stem cell usage should be extensively assessed, along with their corresponding safeguard strategies.
  2. Allogeneic Application: Autologous cell therapy may not be viable for patients with genetic abnormalities. However, multiple types of stem cells, such as iPSCs, appear to possess immunomodulatory properties, making their allogeneic application potentially immune-tolerated by the recipient.
  3. Novel Methods to Reprogram Pluripotent/Multipotent Stem Cells: Innovative techniques for acquiring stem cells are crucial for advancing the field and overcoming current limitations.

Dr. Chenshuang Li
Dr. Zhong Zheng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tissue regeneration
  • stem cell
  • cell reporgramming
  • iPSCs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 846 KiB  
Review
Recent Stem-Cell-Based and Stem-Cell-Free Possibilities for the Therapeutic Management of the Osteonecrosis of the Jaw
by Merita Mazreku, L’uboš Danišovič, Martin Klein and Mária Kleinová
Biomolecules 2025, 15(4), 595; https://doi.org/10.3390/biom15040595 - 16 Apr 2025
Viewed by 213
Abstract
Osteonecrosis of the jaw (ONJ), including the maxilla and mandible, is considered a challenging therapeutic problem, mainly due to the lack of understanding of its pathogenesis. It is well known that ONJ is a severe side effect caused by certain medications used to [...] Read more.
Osteonecrosis of the jaw (ONJ), including the maxilla and mandible, is considered a challenging therapeutic problem, mainly due to the lack of understanding of its pathogenesis. It is well known that ONJ is a severe side effect caused by certain medications used to treat bone metastasis and osteoporosis, such as bisphosphonates, which inhibit bone resorption. Other therapeutics with similar side effects are, for instance, receptor activators of nuclear factor kappa-B ligand (RANK-L) inhibitor (denosumab), tyrosine kinase inhibitors (sunitinib), and antiangiogenics (bevacizumab). The conservative or surgical treatment of these medication-related osteonecroses of the jaw (MRONJs) is generally effortful and still not entirely effective. Therefore, the research seeks alternative treatment options like tissue engineering and stem cell therapy, which predominantly represent mesenchymal stem cells (MSCs) and their derivatives, such as extracellular vesicles. Moreover, it was published that novel stem cell therapy could even prevent the onset of MRONJ. On the other hand, the administration of stem cells may also be accompanied by some other health risks, such as an increased chance of cancer metastasis occurrence in cancer patients. The current review paper summarizes the most recent progress in stem-cell-based and stem-cell-free treatment options for the ONJ. Similarly, we discuss this novel approach’s future perspectives and possible obstacles. Full article
(This article belongs to the Special Issue Stem Cells in Musculoskeletal Tissue Engineering)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop